Indivior (INDV) on Monday said that it will cancel its secondary listing on the London Stock Exchange, effective July 25, ...

Drug maker Indivior has announced plans to delist its shares from the London Stock Exchange (LSE), marking the latest company ...

Pharmaceutical firm Indivior has announced it will soon delist from the London Stock Exchange, keeping its primary listing on the Nasdaq.

Drugmaker Indivior has announced plans to cancel its secondary listing in London, just a year after moving its primary ...

Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align ...

Indivior, a pharmaceutical firm specializing in opioid addiction treatments, plans to delist from the London Stock Exchange ...

Drug maker Indivior has announced plans to delist its shares from the London Stock Exchange (LSE), marking the latest company ...

Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patrick Barry as Chief Commercial Officer, effective June 2. In this role, Barry will lead the company's commercial growth strategy, ...

Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of ...

Indivior said it would cancel its listing on the London Stock Exchange and keep its primary listing on New York City's Nasdaq stock exchange.

(Reuters) -Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and ...

As it works to send opioid use disorder (OUD) treatment Sublocade back into its prior growth territory, Indivior is switching ...